Registry for patients with metastatic lobular breast cancer
Improving Survival for Those With Metastatic Lobular Breast Cancer Through Development of the Multi-center PLUMB Registry-a Prospective Study of LobUlar Metastatic Breast Cancer
This study is collecting information from patients with metastatic lobular breast cancer to see how they respond to treatments and understand their overall health over time.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 12 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 4 sites (San Diego, California and 3 other locations) |
| Trial ID | NCT05964504 on ClinicalTrials.gov |
What this trial studies
This observational registry aims to collect data from patients with invasive lobular carcinoma (ILC) of the breast to develop a specific response assessment tool. The study will evaluate the feasibility of a histologic-based registry and analyze treatment patterns, natural history, and overall survival using real-world data. Participants will be recruited during clinic visits and will provide blood samples at various evaluation points, with follow-up until loss to follow-up, death, or withdrawal from the registry.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with histologically confirmed invasive lobular carcinoma.
Not a fit: Patients with early-stage breast cancer (Stage I-III) or those without lobular histology on tumor biopsy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment strategies for patients with metastatic lobular breast cancer.
How similar studies have performed: While this approach is observational and builds on existing knowledge, similar studies have shown promise in understanding metastatic breast cancer dynamics.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed invasive lobular carcinoma. Mixed lobular/ductal cancer is allowed. 2. Age \>=18 years 3. Any receptor subtype. 4. Ability to understand a written informed consent document, and the willingness to sign it. Exclusion Criteria: 1. Stage I-III breast cancer. 2. Lack of lobular histology on tumor biopsy. 3. Other active cancer (prior treated cancer with no current evidence of disease is allowed).
Where this trial is running
San Diego, California and 3 other locations
- University of California, San Diego — San Diego, California, United States (Recruiting)
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
- Abramson Cancer Center — Philadelphia, Pennsylvania, United States (Recruiting)
- MD Anderson Cancer Center — Houston, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Rita Mukhtar, MD — University of California, San Francisco
- Study coordinator: Astrid Quirarte
- Email: Astrid.Quirarte@ucsf.edu
- Phone: 415-476-8390
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.